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Abstract
Introduction: High blood pressure (BP) leads to target organ damage. It is
suggested that regression of early organ lesions is possible on condition of BP
normalization. The study objective was to assess whether permanent reduction
of BP to the recommended values modifies renal vascular response to acute
angiotensin II inhibition in the Doppler captopril test (DCT) in patients with
essential hypertension (EH). 
Material and methods: Twenty-nine persons (58 kidneys) were found eligible
for the study: 18 patients with EH and 11 healthy volunteers constituting the
control group. Glomerular filtration rate estimation (eGFR), 24-h ambulatory BP
monitoring (ABPM) and DCT with evaluation of renal resistive index change (∆RI)
were performed before and after a 6-month period of intensive antihypertensive
therapy (IAT). Additional ABPM was performed at the end of IAT.
Results: The mean IAT period was 8.5 ±2.4 months. The mean 24-h values of
systolic and diastolic BP in the EH group were significantly lower in the IAT period
than at the beginning and at the end of the study. Significantly lower systolic
and diastolic BP (p < 0.05) and improvement of renal function (eGFR 121 ±38 vs.
139 ±40 ml/min, p < 0.001) were found after IAT as compared to initial values.
Before IAT, ∆RI was significantly lower in the EH group as compared to the
controls, but no such differences were found after IAT.
Conclusions: In EH patients, intensive BP lowering to the recommended values
was associated with improvement of renal function and normalisation of renal
vascular response to acute angiotensin II inhibition.
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Introduction
Arterial hypertension is an epidemic disease. Essential hypertension
(EH) constitutes 90-95% of cases of this disease, and its development is
associated with the interaction of genetic, environmental and demographic
factors. Progression of arterial hypertension leads to remodelling of the
arterial wall and a further increase of already elevated peripheral resistance,
especially in small vessels [1]. Structural changes of the vascular wall result
in its decreased compliance, increased stiffness and acceleration of the
pulse wave velocity and a further increase in vascular resistance. Intrarenal
increase of arterial resistance and impaired renal autoregulation in EH is
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probably caused by local elevation of angioten  sin II
(Ang II), the greater concentration of which
contributes to development of hypertension and
renal injury [2]. Renal vascular resistance and
arterial compliance are together expressed in the
Doppler examination as the renal resistive index
(RI) [3]. Change of RI due to acute inhibition of Ang II
with captopril depends mainly on the level of local
Ang II concentration and thus could reflect the
efficacy of renal autoregulation [4]. In clinical
conditions it is assessed in the Doppler captopril
test (DCT) involving calculation of the difference
between values of the renal resistive index before
and after oral captopril administration [5-8]. In the
studies conducted so far, a significant effect of
blood pressure and duration of EH on elevated
resistive index in intrarenal arteries, reflecting 
the advancement of organ lesions in the course 
of EH, was evidenced [9-13]. In view of these
complications, the current guidelines for the
management of hypertension consistently recom  -
mend lowering the mean daily blood pressure 
to < 125-130/80 mmHg, and only values below 
120/80 mmHg are considered optimal [14]. The study
objective was to assess whether consistent reduction
of blood pressure (BP) to the recom  mended values
modifies renal vascular response to acute Ang II
inhibition in the DCT in patients with EH. 
Material and methods
Twenty-nine persons (58 kidneys) were enrolled
in the study and divided into two groups: 1) EH
group – 18 patients with essential hypertension, 
2) control group – 11 healthy volunteers. Patients
were recruited from consecutive subjects who had
been admitted to the Nephrology Department over
a one-year period. Baseline characteristics of studied
groups are shown in Table I. Exclusion criteria
included renal insufficiency with serum creatinine
levels > 3 mg/dl; glomerular, tubulointerstitial and
obstructive renal diseases; heart and liver failure;
diabetes; renal artery stenosis; intolerance of or
allergy to angiotensin-converting enzyme inhibitors;
and ongoing treatment with non-steroidal anti-
inflammatory drugs. The study was conducted in
two stages (Figure 1), before (S-0) and after (S-1) 
a 6-month period of controlled and intensive
antihypertensive therapy (IAT). 
Target BP level was 125/80 mmHg according to
recommendations for ABPM measurements [14].
Antihypertensive treatment (β-blockers, calcium
channel blockers, angiotensin-converting enzyme
inhibitors and thiazide diuretics) was modified
according to BP control. Depending on the value of
baseline 24-h ambulatory blood pressure monitoring
(ABPM), new antihypertensive medications were
added or changed; increasing the doses was less
frequent. If home blood pressure was higher than
135/85 mmHg after the first month of treatment, only
the doses of already prescribed medications were
increased. The tests of each stage were performed
after a 5-day washout period without antihy  perten  -
sive drugs, except β-blockers if they were used. These
tests included estimation of glomerular filtration rate
(eGFR) by the Cockcroft-Gault formula, ABPM and the
Doppler captopril test. 24-h Ambulatory blood pressure
monitoring was also performed during controlled
antihypertensive treatment, 7–10 days before S-1
tests. 
Ultrasound examinations were performed using
the LOGIQ 400 ultrasonograph (GE), with a convex
transducer, with operating frequency of 3.5–5 MHz.
The renal resistive index (RI) in segmental and
interlobar arteries of the kidneys was calculated on
the basis of Pourcelot’s equation as the ratio of the
difference between the maximum systolic velocity
(Vs) and the end-diastolic velocity (Vd) to the
maximum systolic velocity: RI = (Vs – Vd)/Vs [15].
Resitive index for each kidney was a mean of 
3–5 measurements performed in the upper middle
and lower regions of the renal sinus. The record of
the Doppler spectrum was obtained after an angle
correction of ≤ 60° to the vessel axis.
The Doppler captopril test involved RI asse  -
ssment performed before (Phase 0) and 60 mi  n
after oral administration of 50 mg of captopril
(Phase 1), with arterial pressure measurement on
Parameter Controls EH groupV alue of p
(n = 11) (n = 18)
Age [years] 34.4 ±12.7 37.3 ±11.3 NS
Gender 6 M + 5 F 11 M + 7 F NS
BMI [kg/m2] 23.8 ±3.8 26.8 ±4.5 NS
Smoking [years] 0 0 (0-25) NS
EH duration  0 2 (0.25-15.0) < 0.001
[years]
LDLs [mg/dl] 97.8 ±20.9 119.4 ±29.7 < 0.05
Creatinines 0.85 ±0.16 0.99 ±0.39 NS
[mg/dl]
CRPs [mg/dl] 0.13 ±0.14 0.09 ±0.08 NS
UAER  13.3 ±8.7 8.8 (4.0-265.0) NS
[g/24 h]
Table I. Baseline characteristics of studied groups
UAER – urinary albumin excretion rate, s – serum, NS – non-significant
Figure 1. Study protocol diagram
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the brachial artery performed each time (Figure 2)
[6-8, 16].
Renal response to Ang II inhibition was
calculated as the change of the renal resistive index
(∆RI) in the Doppler captopril test based on the
formula:  ∆RI = RI1 – RI0 [8]. The local bioethics
committee approved the protocol of the study.
Statistical analysis
The variables examined were analysed with
Student’s t-test, Wilcoxon or Mann-Whitney test,
as determined by meeting the condition of normal
distribution and a relation between the analysed
variables. Differences between RI values in the 
DCT were assessed by Student’s t-test for related
variables. The relationships between change of
eGFR during IAT and variables (age, BMI, EH
duration, LDL, urinary albumin excretion rate [UAER],
baseline eGFR, magnitude of BP reduction and
numbers of antihypertensive drugs) were examined
by linear regression analyses. 
Results
Eighteen patients with EH examined in both
stages were found eligible for the study. The median
time from EH diagnosis was 2 years (range: 3 months
to 15 years). 24-h Ambulatory blood pressure
monitoring during  intensive antihypertensive therapy
was performed in 15 patients. The mean period of
IAT was 8.5 ±2.4 months. The mean number of
antihypertensive medications taken before S-1 was
significantly higher than before S-0 (1.8 ±1.0 vs. 1.0 ±1.0,
p = 0.002). Modification of antihypertensive drugs
during IAT is presented in Table II. 
Due to ethical reasons, the control group was
tested only in S-0. The DCT results for the control
group and the EH group in both stages are
presented in Table III.
In both groups and both stages, captopril
administration resulted in significant lowering of
systolic and diastolic blood pressure (p < 0.05) but
a significant increase in RI was found only in the
control group. In the EH group, the change of the 
RI was not significant in either of the two stages.
Parameters of renal function and ABPM values in both
stages and also ABPM in the treatment intensification
period are presented in Table IV.
Figure 2. Doppler captopril test diagram
Phase 0 Captopril
50 mg p.o. 60 min
RI0
Phase 0
RI1
Number of  Before IAT IAT
drugs per patient (n = 18) (n = 18)
n Treatment n Treatment
07 – 0 –
1 6 (1 × BB) (5 × BB)
(1 × CCB) 11 (2 × CCB)
(4 × ACE-I) (4 × ACE-I)
2 3 (2 × ACE-I + D) 4 (2 × BB + D)
(1 × CCB + D) (1 × ACE-I + D)
(1 × CCB + D)
3 2 (1 × CCB + ACE-I + D) 1 (1 × CCB + ACE-I + D)
(1 × BB + CCB + D)
4 0 2 (2 × BB + CCB + ACE-I + D)
Table II. Modification of antihypertensive treatment during IAT
BB – β-blocker, CCB – calcium channel blocker, ACE-I – inhibitor of angiotensin-converting enzyme, D – thiazide diuretic
Group RI ∆RI Value of p (phase 0 : 1)
Phase 0P hase 1
Control (n = 11) 0.606 ±0.049 0.616 ±0.054 0.0129 ±0.0114 < 0.004
EH (n = 18) S-0 0.601 ±0.033 0.593 ±0.047 m. –0.0045 (*)
(–0.075 : 0.048) NS
EH (n = 18) S-1 0.591 ±0.042 0.592 ±0.034 m. 0.0030
(–0.0455 : 0.0675) NS
Table III. Comparison of DCT scores
S-0 – stage 0, S-1 – stage 1, *significance level of p < 0.05 vs. the control group, NS – non-significant536 Arch Med Sci 4, August / 2010
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In S-0, in the period of intensive antihypertensive
therapy and in S-1, the values of 24-h BP 
were significantly higher in the EH group as
compared to the control group. At the same time,
the mean 24-h values of systolic and diastolic
pressure in the EH group were significantly lower
in the IAT period than at the beginning and at the
end of the study. Tests of renal function showed
a slight but significant improvement of organ
function after IAT. In multiple regression analyses
only duration of hypertension (β = 1.464, p = 0.002),
magnitude of BP reduction during IAT (β = 1.327,
p = 0.004) and baseline eGFR (β = –0.668, p = 0.02)
significantly affected the improvement of eGFR 
(R2 = 0.600, p < 0.015). Considering  ∆RI variability
in study groups and stages, a significantly lower
value of  ∆RI was found in the EH group in S-0 as
compared to the controls. In S-1, the difference in
∆RI values was not significant (Figure 3).
Discussion
Normal values of the resistive index in intrarenal
arteries in adults are contained within the limits of
0.56-0.70 [9, 17]. Elevated RI values in the elderly
are attributed to lower arterial compliance and an
increase in pulse pressure, characteristic for old age
[18, 19]. Although in our study the groups differed
significantly in 24-h BP values, the baseline
measurement of the RI in patients with EH did not
significantly differ from healthy persons. An increase
in the value of RI after captopril administration was
significant only in the group of healthy persons. 
Examining 15 healthy persons Taniwaki et al.
showed that RI values increased significantly after
an oral dose of captopril (25 mg) in comparison to
the baseline [8]. Veglio et al. obtained similar
findings [20]. In a group of 45 EH patients and 
15 healthy persons, they found a significant increase
in RI after captopril only in healthy persons and
patients with mild arterial hypertension. These
authors also reported that in patients with more
advanced hypertension, the RI change after
captopril was not significant. These reports
correspond to the results of our study, where no
significance of RI change in the DCT was found in
the essential hypertension group, in stages S-0 and
S-1. Nevertheless,   RI obtained in S-0 was
significantly lower in the EH group as compared to
the controls. Undoubtedly, the fact that the mean
value of RI after captopril administration decreased,
which may be attributed to vascular alterations and
haemodynamic impairment due to elevation of
intrarenal Ang II concentration, contributed to this
result. A similar phenomenon, but much more
marked, is observed in haemodynamically
significant renal artery stenosis when RI lowering
after captopril administration exceeds 0.05 [6, 7].
In their studies, Veglio et al. found that the initial
values of the renal resistive index in stenosed renal
arteries did not differ significantly from RI in arteries
without stenosis, and after captopril administration
the RI value significantly lowered in kidneys with
a stenosed artery, while in kidneys with a normal
artery an increase of the RI was found [16]. In our
study, in the EH group, we found a post-captopril
reduction of the resistive index in DCT in S-0 and
Variable Control groupE H  groupV alue of p
(n = 11) (n = 18) EH group
S-0 IAT S-1
SBP [mmHg] 117.5 ±8.3 135.0** ±12.3 125.5* ±8.5 131.3* ±9.8 S-0 : S-1 – NS
S-0 : IAT – < 0.05
P-1 : IAT – < 0.05
DBP [mmHg] 69.9 ±5.3 85.0** ±11.5 77.4* ±7.0 81.7** ±8.5 S-0 : S-1 – NS
S-0 : IAT – < 0.05
S-1 : IAT – < 0.05
eGFR [ml/min] 116.4 ±21.4 121.0 ±38.0 – 138.7 ±39.7 S-0 : S-1 – < 0.001
Table IV. Comparison of ABPM and eGFR in stages and IAT period
S-0 – stage 0, S-1 – stage 1, IAT – period of intensive antihypertensive treatment, significance level vs. the control group: *for p < 0.05 
and **for p < 0.001, NS – non-significant
0.02
0.01
0
–0.01
0.0129
–0.0045
Control groupE H  S-0 EH S-1
0.003
p = 0.042
p = NS
p = NS
Figure 3. Variability of ∆RI in the studied groups
∆
R
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a slight increase of this index in S-1. The stages
were separated by an over 8-month period of
intensive antihypertensive therapy, where the
recommended target values of 24-h BP were
reached.
To assess the probable effect of intensive BP
reduction (and avoid the effect of the drugs) on
vascular properties, both evaluations of DCT were
performed after suitable, although relatively short,
washout periods of 5 days covering double the half-
life time of the used drugs. Most probably, as
a result of intensive antihypertensive therapy, the
renal vascular response to Ang II inhibition, which
did not differ significantly in S-1 from the result
found in healthy persons, in contrast to S-0,
improved. This cause-and-effect relationship seems
to be supported by a significant improvement of
renal function in the EH group in the S-1 stage as
compared to S-0.
Regression of lesions in intrarenal arteries
formed in the course of arterial hypertension is
questionable. Radermacher et al. investigated
a group of 138 patients with hypertension in the
course of haemodynamically significant renal artery
stenosis and found that angioplasty of the stenosed
renal artery in patients with RI > 0.8 does not bring
the expected clinical benefits such as improved
renal function, better control of BP and longer
survival [21]. In this clinical study, the RI value > 0.8
was to reflect  irreversibility of organ lesions in the
course of hypertension and disqualified patients
from invasive treatment. In response to these
reports, in a group of 50 patients with RI > 0.8
selected among 340 patients with unilateral or
bilateral renal artery stenosis, Zeller et al. observed
a significant improvement of renal function after
angioplasty with stenting [22]. Haemodynamically
significant renal artery stenosis is an extreme
example of renal vascular pathology. Due to the
chronic nature and haemodynamic significance of
the process, some lesions in the renal vascular-
interstitial region are irreversible. In earlier stages
of hypertensive disease, the probability of
regression of functional and structural alterations
of intrarenal vessels should be much higher, which
was suggested by Derchi et al. [23]. Strict BP control
is necessary for renoprotection. In our study, 
we demonstrated that significant BP lowering to
the recommended values is associated with
a significant improvement of intrarenal arterial
functional properties and renal function. We found
significant improvement of eGFR (Cockcroft-Gault
formula) corresponding with decrease of serum
creatinine (0.99 vs. 0.92 mg/dl, p = 0.03) in patients
with EH after IAT. This finding is probably related to
the better control of BP . It is suggested that some
groups of antihypertensive medications such as
ACE-I and ARB  can prevent decline of renal
function, irrespective of BP reduction. In our study,
none group of antihypertensive drugs correlated
with rise of eGFR. However, in multivariate linear
regression duration of hypertension, magnitude of
BP reduction during IAT and baseline eGFR
significantly affected the magnitude of eGFR rise
after intensive antihypertensive treatment. This
finding suggests that improvement of renal function
during antihypertensive therapy is possible when
hypertension-related kidney damage is not so
substantial, and is functional and vascular rather
than glomerular and interstitial (longer duration of
hypertension, higher BP reduction during IAT, but
a low baseline eGFR). These data clearly suggest
a beneficial effect of strict BP reduction. On the
other hand, the short period of our study might
have had a crucial impact on such optimistic results.
If the time of observation was longer, there could
be only stabilization or even lowering of eGFR
observed due to time-dependent decline of renal
function.
Undoubtedly, the value of the results of our
study is limited by the young age of investigated
persons, the small size of the study groups,
relatively short washout period and lack of DCT
evaluation at the end of IAT. These facts arise
partially from the necessity to standardise the 
DCT and withdrawal of antihypertensive medicines,
as well as from the burdensome nature of the
conducted tests and frequent follow-up visits. On
the other hand, an advantage of such a study
protocol is the results of the DCT, which are devoid
of an effect of other drugs blocking the renin-
angiotensin-aldosterone system and BP lowering
agents. Owing to the performance of Doppler tests
by the same person, we eliminated the bias arising
from variable measurement methods.
The results of our study confirm the benefits
arising from intensive antihypertensive therapy and
BP reduction to the recommended target values in
patients with EH. 
If our results are confirmed in a larger
randomised study, we will have a strong argument
for more intensive antihypertensive treatment of
patients with EH. 
In conclusion, in the group of patients with
recently diagnosed EH, significant lowering of blood
pressure to the recommended values was
associated with a significant improvement of renal
function and normalisation of renal vascular
response to acute angiotensin II inhibition.
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